Why is ticagrelor preferred over prasugrel and clopidogrel for antiplatelet therapy?

Ticagrelor is Preferred Over Clopidogrel and Prasugrel in Most ACS Patients

In patients with acute coronary syndromes (ACS), ticagrelor is generally preferred over both clopidogrel and prasugrel because it reduces cardiovascular death, myocardial infarction, and stroke compared to clopidogrel, while having fewer contraindications and a broader safety profile than prasugrel.

Why Ticagrelor Over Clopidogrel

The PLATO trial demonstrated that ticagrelor reduces major adverse cardiovascular events (MACE) by 16% compared to clopidogrel, with particular reductions in:

• Cardiovascular death: 4.0% vs 5.1% (p=0.001) 1
• Myocardial infarction: 5.8% vs 6.9% (p=0.005) 1
• All-cause mortality: 4.5% vs 5.9% (p<0.001) 2

The 2016 ACC/AHA guidelines give ticagrelor a Class IIa recommendation (reasonable to use) in preference to clopidogrel for ACS patients treated with either early invasive or ischemia-guided strategies 1. This applies to both NSTE-ACS and STEMI patients, whether managed with PCI or medical therapy alone 1.

Key Advantages of Ticagrelor:

• Faster onset of action: Direct-acting, reversible P2Y12 inhibitor that doesn't require hepatic conversion 2
• More consistent platelet inhibition: Not affected by CYP2C19 genetic polymorphisms that reduce clopidogrel effectiveness in ~30% of patients 3
• Mortality benefit: Reduces all-cause death, not just ischemic events 2
• Broader applicability: Can be used in patients managed medically without revascularization 1

Why Ticagrelor Over Prasugrel

While prasugrel also reduces ischemic events compared to clopidogrel (TRITON-TIMI 38 trial), ticagrelor has critical safety advantages:

Prasugrel's Major Contraindications and Limitations:

1. Absolute contraindication in prior stroke/TIA: Prasugrel caused net harm with 6.5% stroke rate (including 2.3% intracranial hemorrhage) vs 1.2% with clopidogrel in patients with prior stroke/TIA 1, 3

2. No net benefit in elderly patients ≥75 years: Higher bleeding risk without clear efficacy benefit except in high-risk subgroups (diabetes, prior MI) 1, 3

3. No net benefit in low body weight (<60 kg): Increased bleeding without improved outcomes 1, 3

4. Requires known coronary anatomy: In TRITON-TIMI 38, prasugrel was only given after diagnostic angiography confirmed anatomy suitable for PCI 4, 3

5. Higher life-threatening bleeding: Prasugrel increased fatal bleeding compared to clopidogrel 1

Ticagrelor has none of these absolute contraindications and can be administered upstream before coronary anatomy is known 1.

Clinical Decision Algorithm

For ACS Patients (NSTE-ACS or STEMI):

First-line choice: Ticagrelor 180 mg loading dose, then 90 mg twice daily 1, 5, 4

Consider Prasugrel instead if:

• Patient is <75 years old AND
• Weight ≥60 kg AND
• No history of stroke or TIA AND
• Coronary anatomy known and suitable for PCI AND
• Not at high bleeding risk 1, 5

Use Clopidogrel only if:

• Ticagrelor contraindicated (prior intracranial hemorrhage, ongoing bleeding) OR
• Prasugrel contraindicated AND ticagrelor unavailable OR
• Patient unable to take aspirin (use clopidogrel monotherapy) 6, 1

Important Caveats

Bleeding Risk Considerations:

Both ticagrelor and prasugrel increase non-CABG-related major bleeding compared to clopidogrel 1. However:

• Ticagrelor's bleeding increase is primarily non-fatal 2
• The mortality benefit with ticagrelor outweighs bleeding risk in most patients 2, 7
• CABG-related bleeding is actually lower with ticagrelor due to reversible platelet inhibition 8

Aspirin Dosing:

When using ticagrelor, maintain aspirin at 81 mg daily (not higher doses), as high-dose aspirin increases bleeding without improving outcomes 6, 1.

Duration of Therapy:

Continue dual antiplatelet therapy for at least 12 months after ACS, regardless of which P2Y12 inhibitor is used 6, 1, 5.

Real-World Evidence:

Recent real-world studies confirm ticagrelor's superiority over clopidogrel in reducing MACE (HR 0.79) and hospitalizations without increased major bleeding 7. However, a 2025 network meta-analysis raised questions about whether subsequent studies have replicated PLATO's mortality benefit 9, though this doesn't change current guideline recommendations.

The bottom line: Ticagrelor offers the best balance of efficacy and safety for the broadest population of ACS patients, with fewer contraindications than prasugrel and superior outcomes compared to clopidogrel 1, 5, 4.